NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on the Financial Results for the Quarter and Half Year ended September 30, 202012-11-2020
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on the Financial Results for the Quarter and Half Year ended September 30, 2020NATCO PHARMA LTD. - 524816 - 25Th November, 2020 Is The Record Date For Making Payment Of Second Interim Divided For FY 2020-21
25th November, 2020 is the Record date for making payment of Second Interim Divided for FY 2020-21NATCO PHARMA LTD. - 524816 - Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2020
Unaudited Financial Results for the Quarter and Half year ended 30th September, 2020NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The Company will host an Earnings Call with Investors / Analysts at 11.00 a.m. IST on Friday, November 13, 2020 to disseminate Financial Results of the company for the quarter ended September 30, 2020.NATCO PHARMA LTD. - 524816 - Board to consider Q2 results & Second Interim Dividend on Nov 12, 2020
Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on November 12, 2020, inter alia, to consider the following items of business and related matters:1. To consider the Unaudited Financial Results for the quarter and half year ended September 30, 2020.2. To consider second interim dividend, if any, for the financial year 2020-21.Further, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time TRADING WINDOW for dealing in the securities of the Company by the Employee(s) / Director(s) and their immediate relatives will be closed from November 04, 2020 to November 14, 2020 (both days inclusive). Trading window will be opened on November 16, 2020.NATCO PHARMA LTD. - 524816 - Closure of Trading Window
pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time TRADING WINDOW for dealing in the securities of the Company by the Employee(s) I Director(s) and their immediate relatives will be closed from 4th November, 2020 to 14th November, 2020 both days inclusive). Trading window will be opened on 16th November, 2020NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for Notice Of Board Meeting
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2020 ,inter alia, to consider and approve To consider the Unaudited Financial Results for the quarter and half year ended 30th September, 2020 and to consider second interim dividend, if any, for the financial year 2020-21Natco Pharma Ltd - 524816 - Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0330 Name of the Signatory :- M ADINARAYANADesignation :- Company Secretary and Compliance OfficerNatco Pharma Ltd - 524816 - Compliance Certificate For The Quarter Ended September 30, 2020
Compliance Certificate for the quarter ended September 30, 2020Natco Pharma Ltd - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Report for the quarter ended September 30, 2020